Antibody Screening for Anti-Drug Resistance-Associated Mutations (ADRAG) in HIV Treatment
This test checks for genetic changes in HIV that may make certain antiviral medications less effective. It helps doctors tailor treatment to improve response and reduce drug resistance.
["Helps personalize HIV treatment to avoid resistance and improve long-term success."]
Key facts at a glance
- LOINC
- 69563-5
- Short code
- CGLDNA
- Synonyms
- C glabrata DNA Vag Ql NAA+probe
- Category
- chemistry
- Sample
- serum
- Container
- Sterile viral transport medium or sterile container for vaginal swab specimen
- Units
- N/A
- Fasting
- false
- Population
- adult
- Sex
- female
- Age range
- 12–99 years
- Method
- probe-amp-tar
- CPT
- 87481
- SNOMED
- 441924003
- Specimen volume
- 1 vaginal swab in transport medium
- Stability
- Room temperature: 24 hours; Refrigerated (2-8°C): 7 days; Frozen (-70°C or below): 30 days
- Hemolysis max
- 500
- Lipemia max
- 1000
- Icterus max
- 500
- TAT
- 24–72 hours
- Order
- routine
Why This Test Matters in HIV Care
HIV can develop resistance to medications over time if not managed properly. Certain mutations in the virus can alter how it responds to drugs. This test identifies specific genetic variations that might affect treatment effectiveness, allowing doctors to adjust therapy sooner.
How the Test Works
A small blood sample is collected and analyzed using a specialized molecular probe. The test detects mutations linked to resistance to common HIV medications, helping determine if changes in treatment may be needed.
What to Expect Before the Test
No special preparation is needed. You’ll have a standard blood draw, similar to other routine lab tests. The results are typically available within a few days, depending on lab processing.
What the Results Mean
If mutations are found, your healthcare provider will discuss whether adjustments to your treatment plan are necessary. Even if no mutations are detected, this test helps monitor ongoing treatment effectiveness.
Reference range
Negative (Candida glabrata DNA not detected)N/A
Patient should avoid vaginal douching, sexual intercourse, and use of vaginal medications or spermicidal products for at least 24-48 hours prior to specimen collection. Specimen should be collected before antifungal therapy initiation when possible.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
This test is particularly important for patients on long-term HIV therapy. Detecting resistance mutations early can prevent treatment failures, reduce side effects, and improve overall health outcomes. It’s especially useful in settings where drug resistance is a concern, such as in regions with limited access to new medications.
Short name
HIV Drug Resistance Mutation Probe Screen
Frequently asked questions
How often should I get this test?
What if my test shows resistance mutations?
Does this test cover all HIV medications?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy